ArticleCancer immunology, immunotherapy : CII2020
Interleukin-38 in colorectal cancer: a potential role in precision medicine.
Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.International journal of molecular sciences · 2021Pooled it
- Interleukin-38 serum levels in breast cancer: A comparative analysis of women under 40 and over 50.Caspian journal of internal medicine · 2026Article
- Review
- The distinct role of IL-34 and IL-35 in gastric cancer.Frontiers in immunology · 2025Review
- RBM10 inhibits pancreatic cancer development by suppressing immune escape through PD-1 expression.Journal of Cancer · 2025Article
- IL-38 as a Novel Biomarker in Multiple Myeloma Patients: A Prospective Clinical Evaluation.Cancer management and research · 2025Article
- The distinct roles of IL-37 and IL-38 in non-small cell lung carcinoma and their clinical implications.Frontiers in immunology · 2025Review
- Dichotomous roles of IL-36 and IL-38 in cardiovascular disease.Frontiers in immunology · 2025Review
- Investigation of pre and postoperative Th1/Th2 cytokine balance and novel cytokines in colorectal cancer patients.Clinical and experimental medicine · 2024Article
- Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.Frontiers in immunology · 2024Article
- IL-38 promotes the development of prostate cancer.Frontiers in immunology · 2024Article
- The emerging role of IL-38 in diseases: A comprehensive review.Immunity, inflammation and disease · 2023Review
- Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.Clinical and experimental medicine · 2023Article
- Clinical relevance and therapeutic potential of IL-38 in immune and non-immune-related disordersEuropean cytokine network · 2022Review
- Interleukin-38 promotes skin tumorigenesis in an IL-1Rrp2-dependent manner.EMBO reports · 2022Article
- IL-32 and IL-34 in hepatocellular carcinoma.Frontiers in medicine · 2022Review
- The Role of IL-37 and IL-38 in Colorectal Cancer.Frontiers in medicine · 2022Review
- IL-38 Gene Deletion Worsens Murine Colitis.Frontiers in immunology · 2022Article
- The role of IL-38 in intestinal diseases - its potential as a therapeutic target.Frontiers in immunology · 2022Review
- The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related death, partly due to a lack of reliable biomarkers for early diagnosis. To improve the outcome of CRC, it is critical to provide diagnosis at an early stage using promising sensitive/specific marker(s). Using immunohistochemistry and histopathology, IL-38 expression was determined in tissue arrays of CRC with different TNM status and depth of tumour invasion. Data were compared to IL-38 in adjacent non-cancer tissue and correlated with demographic information, including survival. A substantial reduction of IL-38 was detected in the CRC tissue compared to adjacent non-cancer colonic tissue. IL-38 correlated with the extent of tumour differentiation (P < 0.0001); CRC location in the left side of the colon (P < 0.05), and smaller tumour size (≤ 5 cm; P < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated both high specificity and high sensitivity of IL-38 for the diagnosis of CRC [area under the curve (AUC) = 0.89)]. By sub-group analysis, AUC of IL-38 for the diagnosis of CRC was higher in poorly differentiated, right-sided CRC or tumour size > 5 cm (all AUC > 0.9). Significantly, longer survival was observed for the IL-38
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.